newsfilter
← Latest News
GlobeNewswire·

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome

SANTA MONICA, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ:OPNT) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Opiant's pipeline candidate OPN